On December 25th, a reporter from The Paper noticed that several e-commerce platforms now offer diagnosis and treatment services for the Eli Lilly glucose dependent insulinotropic peptide (GIP)/glucagon like peptide-1 (GLP-1) receptor agonist tilboptin (trade name: Mufengda), which is available for purchase on e-commerce platforms. Lilly China stated that the drug is a self funded medication, and the specific price should refer to the pricing of major pharmaceutical institutions.